- Home
- BIVI vs NLSP Comparison
BIVI vs NLSP Comparison
Compare BIVI & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- NLSP
- Stock Information
- Founded
- BIVI 2013
- NLSP 2015
- Country
- BIVI United States
- NLSP Switzerland
- Employees
- BIVI N/A
- NLSP N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- BIVI Health Care
- NLSP Health Care
- Exchange
- BIVI Nasdaq
- NLSP Nasdaq
- Market Cap
- BIVI 15.0M
- NLSP 12.4M
- IPO Year
- BIVI N/A
- NLSP 2021
- Fundamental
- Price
- BIVI $1.60
- NLSP $2.63
- Analyst Decision
- BIVI
- NLSP
- Analyst Count
- BIVI 0
- NLSP 0
- Target Price
- BIVI N/A
- NLSP N/A
- AVG Volume (30 Days)
- BIVI 434.0K
- NLSP 162.6K
- Earning Date
- BIVI 08-15-2025
- NLSP 10-17-2025
- Dividend Yield
- BIVI N/A
- NLSP N/A
- EPS Growth
- BIVI N/A
- NLSP N/A
- EPS
- BIVI N/A
- NLSP N/A
- Revenue
- BIVI N/A
- NLSP N/A
- Revenue This Year
- BIVI N/A
- NLSP N/A
- Revenue Next Year
- BIVI N/A
- NLSP N/A
- P/E Ratio
- BIVI N/A
- NLSP N/A
- Revenue Growth
- BIVI N/A
- NLSP N/A
- 52 Week Low
- BIVI $1.46
- NLSP $1.30
- 52 Week High
- BIVI $75.00
- NLSP $7.40
- Technical
- Relative Strength Index (RSI)
- BIVI 21.13
- NLSP 60.48
- Support Level
- BIVI $1.46
- NLSP $2.35
- Resistance Level
- BIVI $1.84
- NLSP $2.65
- Average True Range (ATR)
- BIVI 0.40
- NLSP 0.21
- MACD
- BIVI 0.02
- NLSP 0.07
- Stochastic Oscillator
- BIVI 3.08
- NLSP 84.16
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.